Latest From Agena Bioscience
Agena Bioscience will launch two diagnostic panels for targeted testing of lung and colon cancer in Europe in January. The liquid biopsy technology is based on its benchtop mass spectrometer, the MassArray Dx Analyzer 4.
The use of mass spectrometry in IVD applications looks to be gaining momentum. In this article, Alina Kim, Sunayana Karra and Akash Kundu of Boston Biomedical Consultants report on new developments and innovations showcased at the American Association for Clinical Chemistry Annual (AACC) & Clinical Lab Expo (CLE) annual meeting that took place this summer. Players at the convention exhibited a range of Class I medical devices, research use only liquid chromatography tandem mass spectrometry (LC-MS/MS), matrix-assisted laser desorption/ionization (MALDI-TOF), inductively coupled plasma mass spectrometry (ICP-MS), sample preparation automation platforms, and software solutions.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The coming of autumn has brought a flurry of personnel changes in Asia, with China oncology startup BeiGene continuing its expansion by hiring more executives, while two genome testing firms have set up R&D subsidiaries in China, further heating up the competition in a red hot area. Change has also taken place at the top of the US industry association PhRMA.
Drug Discovery Tools
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Agena Bioscience
- Senior Management
- Peter Dansky, CEO
- Contact Info
Phone: (858) 202-9000
3565 General Atomics Court
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.